Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus
A rare case report and a review of the literature
Jingjing Zhou, MDa, Dongfeng Li, MDa, Qiansong Cheng, MDib,*

Abstract
Rationale: Fibrates are widely used to control hypertriglyceridemia and mixed dyslipidemia alone or in combination with statins. These drugs have rare, but severe and potentially vital adverse reactions of rhabdomyolysis and secondary acute renal failure (ARF). The objective of this article is to analyze this adverse effect of fibrates and ensure the safety of drug use.

Patient concerns: We report a case of rhabdomyolysis and ARF due to fenofibrate monotherapy in a 68-year-old female with post-pancreatitis diabetes mellitus and review reported cases of rhabdomyolysis correlated with fibrates monotherapy.

Diagnosis: The patient was diagnosed with rhabdomyolysis associated with fenofibrate monotherapy as confirmed by symptoms of fatigue and muscle pain, and elevated levels of myoglobin and creatine kinase.

Interventions: Fenofibrate therapy was discontinued. Moreover, intravenous fluids, urinary alkalization, and diuretic were performed.

Outcomes: The symptoms were completely relieved, and relevant laboratory indexes returned to normal range during follow-up.

Lessons: Physicians should be aware of the side effect of rhabdomyolysis of fibrates, and patients should also be informed about this potential side effect, especially for patients with high-risk factors. A favorable outcome can be achieved by timely diagnosis and prompt treatment.

Abbreviations: ARF = acute renal failure, CK = creatine kinase, CRRT = continuous renal replacement therapy, DM = diabetes mellitus, TSH = thyroid stimulating hormone, TT3 = total thyroxin 3, TT4 = total thyroxin 4.

Keywords: acute renal failure, diabetes mellitus, fenofibrate, pancreatitis, rhabdomyolysis

1. Introduction
Fibrates are widely used as effective drugs in the treatment of diabetic hypertriglyceridemia and mixed dyslipidemia alone or in combination with statins.[11] Frequent side effects of fibrates are gastrointestinal discomfort, musculoskeletal symptoms, vertigo, headache, anxiety, skin rash, and loss of libido.[12-13] Rhabdomyolysis is often associated with myoglobinuria and acute renal failure (ARF), which is a rare but serious adverse event of fibrates monotherapy. The risk of rhabdomyolysis with fenofibrate monotherapy increases in patients with hypothyroidism, diabetes mellitus, renal disease, female gender, and/or older age.[14] Here, we report a novel case of rhabdomyolysis induced by fenofibrate monotherapy in a patient with post-pancreatitis diabetes, and review the reported cases of rhabdomyolysis associated with fibrates monotherapy. Informed consent was obtained from the patient for publication of the case.

2. Case report
A 68-year-old female patient was admitted to our hospital with complaints of fatigue, muscle pain, and a decreased urine output for the previous 2 weeks. She had a history of diabetes mellitus after acute pancreatitis for nearly 11 years, accompanied by peripheral vascular disease and peripheral neuropathy. Moreover, she had suffered from dyslipidemia for about 2 years. Her regular medications included insulin (totaling 16 units daily) and mecobalamin (3 tablets daily). 250 mg micronized fenofibrate daily was initiated to control hypertriglyceridemia 5 months ago. She had no history of liver, muscle, or kidney disease, and had not caught a cold recently. She also denied hypertension, coronary heart disease, or thyroid disease. Diffuse tenderness of muscles
and pretibial edema were detected on physical examination. No obvious abnormality was found in chest X-ray, abdominal ultrasonography, and cardiac ultrasonography. The electrocardiogram showed sinus rhythm without alteration of ST segment. On the basis of the above data, there was no evidence of acute myocardial infarction.

The results of the laboratory examination on admission were as follows: creatine kinase (CK): 8384.6 IU/L (normal: 24–174 IU/L), aspartate aminotransferase: 716 IU/L (normal: 0–40 IU/L), alanine aminotransferase: 68 IU/L (normal: 0–40 IU/L), lactate dehydrogenase: 1244 IU/L (normal: 103–227 IU/L), serum creatinine: 97.63 μmol/L (normal: 41–81 μmol/L), blood urea nitrogen: 14.79 mmol/L (normal: 1.7–8.3 mmol/L), myoglobin: 1075 ng/mL (normal: 25–72 ng/mL), troponin T: 37.28 ng/L (normal: 0–14 ng/L). Antinuclear antibody, anti-JO-1 antibody, anti-double-stranded DNA antibody, anti-centromere antibody, anti-mitochondrial antibody M2, and rheumatoid factor were all negative. Thyroid stimulating hormone (TSH), total thyroxin 3 (TT3), and total thyroxin 4 (TT4) were normal. Double-stranded DNA antibody, anti-centromere antibody, anti-mitochondrial antibody were normal. The patient was cured. Due to the severe side effect, the patient did not resume lipid-lowering therapy with fenofibrate or other hypolipidemic drugs during follow-up. Through diet and exercise, the blood lipid control of the patient was poor and triglyceride gradually increased (data not shown). Therefore, for patients with fenofibrate-induced rhabdomyolysis, how to choose appropriate lipid-lowering drugs is a challenge, which needs further research.

Up to date, only a few cases of rhabdomyolysis induced by fibrates monotherapy have been reported. Here, we reported a novel case of fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus (DM). The present report depicted a diabetic patient with only a history of hypertriglyceridemia and acute pancreatitis, without other past medical history and medication history. The patient was diagnosed with rhabdomyolysis on the basis of fatigue, muscle pain, oliguria, marked increases in CK, and myoglobin. After discontinuation of fenofibrate, hydration, alkalinization, and diuresis, the patient was cured. Due to the severe side effect, the patient did not resume lipid-lowering therapy with fenofibrate or other hypolipidemic drugs during follow-up. Through diet and exercise, the blood lipid control of the patient was poor and triglyceride gradually increased (data not shown). Therefore, for patients with fenofibrate-induced rhabdomyolysis, how to choose appropriate lipid-lowering drugs is a challenge, which needs further research.

Until now, the definite association between fibrates and rhabdomyolysis remains unclear. Fibrates may affect cholesterol biosynthesis and lead to changes in the constitution and function of the muscle fibre’s plasma membrane.[7] Emergence of muscle necrosis and increase in muscular lipoproteinlike activity may also be the underlying mechanisms of fibrates-induced rhabdomyolysis.[3][7] It is demonstrated that fibrates can induce specific cell injury to human embryonal rhabdomyosarcoma cells through activation of peroxisome proliferator-activated receptor-α (PPARα).[8] Therefore, activation of PPARα-signaling pathway may be an important mechanism of fibrates-induced rhabdomyolysis.

Fenofibrate monotherapy-induced, and diabetes-related rhabdomyolysis were rarely reported, with only 5 cases having been described in English literature.[9–13] We present an additional case, which is the first report of rhabdomyolysis induced by fenofibrate monotherapy in a patient with post-pancreatitis DM. DM is associated with decreased mitochondrial and stem cell functions in skeletal muscle cells. These dysfunctions can affect cell homeostasis and lead to muscle disorders in diabetic patients.[14] These abnormalities may also make muscle cells susceptible to other factors causing muscle damage and increase the risk of rhabdomyolysis. The level of circulating proinflammatory cytokines, including IL-6, TNF-α, and monocyte chemoattractant protein (MCP)-1, increases significantly in patients after acute pancreatitis.[15] Circulating IL-6 may participate in mitochondrial DNA damage and iron dyshomeostasis of skeletal muscle cells, which is implicated in muscle aging. This maybe one of the potential risk factors for rhabdomyolysis.[16] Due to the scarcity of cases, the exact mechanism of fenofibrate-induced rhabdomyolysis in diabetic patients, especially in post-pancreatitis DM patients, remains unclear and needs further study.

For an in-depth study and a preferable understanding of patient characteristic, risk factor, clinical management, and prognosis of this adverse effect, we made further efforts to search for studies of rhabdomyolysis induced by fibrates monotherapy in the PubMed database. The relevant studies reported in the English-language literature were searched from onset to August 20, 2019 using the following terms: fibrates, gemfibrozil, fenofibrate, ciprofibrate, bezafibrate, and rhabdomyolysis. Due to severe adverse reactions of clofibrate and rare utilization of it at present, the cases of rhabdomyolysis associated with clofibrate were excluded. Moreover, the references of all included articles

---

**Table 1** Relevant laboratory values of our patient after the admission.

| Variable                  | Day after admission | Reference range |
|---------------------------|---------------------|-----------------|
| Creatinine kinase (IU/L)  | 8384.6              | 24–174          |
| Creatinine (μmol/L)       | 97.6                | 14.79 mmol/L    |
| Myoglobin (ng/mL)         | 1075                | 1244 IU/L       |

---

Zhou et al. Medicine (2020) 99:21
Table 2
Summary of 31 previously reported cases (30 articles) of rhabdomyolysis associated with fibrates monotherapy and the present case.

| Variable | Cases of rhabdomyolysis |
|----------|-------------------------|
| Sex, n (%) | | |
| Male | 15 (47%) |
| Female | 17 (53%) |
| Mean age, age (range) | 55 (26–82) |
| Medical history, n (%) | | |
| Hypertension | 21 (65.6%) |
| Diabetes mellitus | 11 (34.3%) |
| Chronic renal failure | 7 (21.9%) |
| Hypothyroidism | 4 (12.5%) |
| Mean fibrates monotherapy duration (range), wk | 17.5 (3d–3yr) |
| Mean level of serum creatinine (range), μmol/L | 442 (97.2–1370.2) |
| Secondary acute renal failure, n (%) | 28 (87.5%) |
| Treatment, n (%) | | |
| Discontinuation drugs + hydration, alkalinization, and/or diuretic | 16 (50%) |
| Only discontinuation drugs | 6 (18.8%) |
| Discontinuation drugs + hemodialysis or CRRT | 7 (21.9%) |
| Discontinuation drugs + plasma exchange | 1 (3.1%) |
| Not reported, n | 2 (6.2%) |
| Outcome, n (%) | | |
| Recovery | 21 (65.6%) |
| Improved | 7 (21.9%) |
| Died | 2 (6.2%) |
| Not reported | 2 (6.2%) |

*CRRT = continuous renal replacement therapy.*

were manually retrieved to ensure that no cases were lost. The cases were excluded if they fulfilled the following criteria:

1. no detailed patient, clinical, and laboratory records, and/or
2. used in combination with statins or other drugs that had a causal relationship with rhabdomyolysis.

A total of 31 cases of rhabdomyolysis induced by fibrates monotherapy were found, including 16 cases of fenofibrate,[4,5,9–13,17–25] 8 cases of bezafibrate,[26–32] 5 cases of gemfibrozil,[33–37] and 2 cases of cipofibrate.[38,39] All clinical and laboratory data were summarized in Table 2. There was no apparent gender difference in fibrates monotherapy-induced rhabdomyolysis. Rhabdomyolysis frequently occurred in people with advanced age, hypertension, DM, chronic renal failure, and/or hypothyroidism. Therefore, these may be potential risk factors for rhabdomyolysis associated with fibrates monotherapy. Time of reaction initiation varied between 3 days and 3 years (the average time was 17.5 weeks). Most patients with rhabdomyolysis were complicated with secondary ARF. Most sufferers can be cured by discontinuation of fibrates, or in combination with hydration, alkalinization, and diuresis. Other strategies were needed for few cases with severe renal insufficiency, including hemodialysis, continuous renal replacement therapy (CRRT), and plasma exchange. The prognosis of rhabdomyolysis was well, and most patients can recover and improve.

4. Conclusion

We report a novel case of fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis DM, and literature review as well as our case observation suggests that

prescribers and users of fibrates should be mindful to its rare, but potentially fatal adverse effects such as rhabdomyolysis and secondary ARF. For patients taking fibrates, risk factors such as old age, hypertension, DM, chronic renal failure, and hypothyroidism should be regarded. Satisfactory results can be achieved by timely diagnosis and effective treatment for patients with fibrates-induced rhabdomyolysis.

Author contributions

Conceptualization: Jingjing Zhou.

Data curation: Jingjing Zhou, Dongfeng Li.

Supervision: Dongfeng Li, Qiansong Cheng.

Writing – original draft: Jingjing Zhou.

Writing – review & editing: Jingjing Zhou, Qiansong Cheng.

References

[1] Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341:498–511.

[2] Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fibrate therapy. Am J Cardiol 2007;99:3C–8C.

[3] Baer AN, Wortmann RL. Myotoxicity associated with lipid-lowering drugs, Currie Opin Rheumatol 2007;19:67–73.

[4] Wang D, Wang Y. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: a rare case report and literature review. Medicine 2018;97:e0318.

[5] Wu J, Song Y, Li H, et al. Rhabdomyolysis associated with fibrate therapy review of 76 published cases and a new case report. Eur J Clin Pharmacol 2009;65:169–74.

[6] Czraky MJ, Willey VJ, McKenney JM, et al. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol 2013;7:102–8.

[7] Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 2002;128:159–68.

[8] Maiguma T, Fujisaki K, Itoh Y, et al. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. Naunyn Schmiedebergs Arch Pharmacol 2003;367:289–96.

[9] Barker BJ, Goodenough RR, Fallo JK. Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care 2003;26:2482–3.

[10] Cetinkaya R, Uyanik A, Yildirim R, et al. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with type-2 diabetes. Indian J Med Sci 2008;62:458–9.

[11] Daris R, Akbulut S, Ozmen S, et al. Rhabdomyolysis-induced acute renal failure following fenofibrate therapy: a case report and literature review. Case Rep Med 2010;2010.

[12] Uşküdar Çansu D, Yaşar NS, Korkmaz C. Acute renal failure due to fenofibrate monotherapy. Anadolu Kardiyol Derg 2011;11:371–2.

[13] Soyoral YU, Canbaz ET, Erdur MF, et al. Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus. J Pak Med Assoc 2012;62:49–51.

[14] Fujimaki S, Kubwabara T. Diabetes-induced dysfunction of mitochondria and stem cells in skeletal muscle and the nervous system. Int J Mol Sci 2017;18: pii: E2147.

[15] Pendlharkar SA, Singh RG, Petrov MS. Pro-inflammatory cytokine-induced lipolysis after an episode of acute pancreatitis. Arch Physiol Biochem 2018;124:401–9.

[16] Pecca A, Mankowski RT, Kamenov G, et al. Advanced age is associated with iron dyshomeostasis and mitochondrial DNA damage in human skeletal muscle. Cells 2019;8: pii: E1525.

[17] Clouâtre Y, Leblanc M, Ouimet D, et al. Feno floride-induced rhabdomyolysis. Anadolu Kardiyol Derg 2011;11:371–2.

[18] Ghosh B, Goodenough RR, Falko JM. Feno floride-induced rhabdomyolysis. Arch Physiol Biochem 1999;105:1–8.

[19] Satarasinghe RL, Ramesh R, Riyaaz AA, et al. Hypothyroidism is a predisposing factor for fenofibrate-induced rhabdomyolysis-patient report and literature review. Drug Metabol Drug Interact 2007;22: 279–83.

[20] Tahmaz M, Kumbasar B, Ergen K, et al. Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis. Ren Fail 2007;29: 927–30.
[21] Yildiz A, Gucuk E, Cay S. A case of rhabdomyolysis and thromboembolic event secondary to fibrate monotherapy. Acta Cardiol 2008;63:515–7.

[22] Sousa AA, Kronit HS, Neves Fde A, et al. Fenofibrate-induced rhabdomyolysis in a patient with chronic kidney disease: an unusual presenting feature of hypothyroidism. Arq Bras Endocrinol Metabol 2009;53:383–6.

[23] Kato K, Nagase A, Matsuda M, et al. Rhabdomyolysis associated with fenofibrate monotherapy in a patient with chronic myelogenous leukemia. Case Rep Gastroenterol 2011;5:492–6.

[24] Erdur FM, Soyoral YU, Emre H, et al. Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report. Clin Biochem 2012;45:162–4.

[25] Kiskac M, Zorlu M, Cakirca M, et al. A case of rhabdomyolysis complicated with acute renal failure after resumption of fenofibrate therapy: a first report. Indian J Pharmacol 2013;45:305–6.

[26] Habenstock A, Schröcksnadel W, Bauer K, et al. Predominance of lactate dehydrogenase isoenzyme 1 in a patient with bezafibrate-induced rhabdomyolysis. Clin Chem 1984;30:1587–8.

[27] Malnick SD, Badir A, Landau Z. Bezafibrate-induced rhabdomyolysis. DICP 1991;25:369–70.

[28] Kanterewicz E, Sanmartí R, Riba J, et al. Bezafibrate-induced rhabdomyolysis. Ann Rheum Dis 1992;51:536–8.

[29] Göröz JL, Sancho A, Alcoy E, et al. Rhabdomyolysis and acute renal failure associated with bezafibrate treatment. Nephrol Dial Transplant 1995;10:2371–2.

[30] Terrovitou CT, Milonis HJ, Elsaf MS. Acute rhabdomyolysis after bezafibrate re-exposure. Nephron 1998;78:336–7.

[31] Kamalah MD, Sanjay LD. Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. Singapore Med J 2001;42:368–72.

[32] Yang KC, Fang CC, Su TC, et al. Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD. Am J Kidney Dis 2005;45:e57–60.

[33] Göröz JL, Sancho A, Lopez-Martín JM, et al. Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy. Nephron 1996;74:437–8.

[34] Atmaca H, Sayarlioglu H, Kulah E, et al. Rhabdomyolysis associated with gemfibrozil-colchicine therapy. Ann Pharmacother 2002;36:1719–21.

[35] Yen TH, Chang CT, Wu MS, et al. Acute rhabdomyolysis after gemfibrozil therapy in a pregnant patient complicated with acute pancreatitis and hypertriglyceridemia while receiving continuous venovenous hemofiltration therapy. Ren Fail 2003;25:139–43.

[36] Layne RD, Sebahi AS, Stark IJ. Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. Ann Pharmacother 2004;38:232–4.

[37] Hahn M, Sriraran K, McFarland MS. Gemfibrozil-induced myositis in a patient with normal renal function. Ann Pharmacother 2010;44:211–4.

[38] Fontaine C, Guard-Schmid JB, Slama L, et al. Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate. AIDS 2003;17:1927–8.

[39] dos Santos AG, Guardia AC, Pereira TS, et al. Rhabdomyolysis as a clinical manifestation of association with ciprofibrate, sirolimus, cyclosporine, and pegylated interferon-a in liver-transplanted patients: a case report and literature review. Transplant Proc 2014;46:1887–8.